SCHEMBL2864883

SCHEMBL2864883

CC(=O)c1ccc(-c2cccc(Nc3cc(C)ccn3)n2)s1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KARS1 Q15046 12/20 0.56
SYK P43405 2/20 0.50
JAK2 O60674 1/20 0.46
MEN1 O00255 3/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
KMT2A Q03164 3/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
KDR P35968 1/20 0.44
KCNN1 Q92952 1/20 0.42
KCNN2 Q9H2S1 1/20 0.42
KCNN3 Q9UGI6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13136552 0.91 KARS1 (0.56) KARS1SYKJAK2MEN1NPC1
SCHEMBL2869562 0.90 KARS1 (0.55) KARS1SYKJAK2MEN1NPC1
SCHEMBL13177675 0.89 KARS1 (0.54) KARS1SYKJAK2MEN1NPC1
SCHEMBL13136551 0.89 KARS1 (0.54) KARS1SYKJAK2MEN1NPC1
SCHEMBL2856828 0.89 KARS1 (0.54) KARS1SYKJAK2MEN1NPC1
SCHEMBL13136607 0.88 KARS1 (0.42) KARS1SYKJAK2KDM4EALDH1A1
SCHEMBL13136554 0.88 KARS1 (0.53) KARS1SYKJAK2MEN1NPC1
SCHEMBL13136575 0.88 KARS1 (0.53) KARS1SYKJAK2MEN1NPC1
SCHEMBL13136576 0.88 KARS1 (0.53) KARS1SYKJAK2MEN1NPC1
SCHEMBL2869691 0.87 SYK (0.51) KARS1SYKJAK2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1854793-A1 NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY Japan Tobacco, Inc. (JP) 2007-11-14 EP claimed
US-20060205731-A1 Novel aminopyridine compounds having Syk inhibitory activity JAPAN TOBACCO INC. (JP) 2006-09-14 US claimed
US-7803801-B2 Aminopyridine compounds having Syk inhibitory activity JAPAN TOBACCO, INC. (JP) 2010-09-28 US disclosed
US-7803801-B2 Aminopyridine compounds having Syk inhibitory activity JAPAN TOBACCO, INC. (JP) 2010-09-28 US disclosed
US-7803801-B2 Aminopyridine compounds having Syk inhibitory activity JAPAN TOBACCO, INC. (JP) 2010-09-28 US disclosed
EP-1854793-A1 NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY Japan Tobacco, Inc. (JP) 2007-11-14 EP disclosed
EP-1854793-A1 NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY Japan Tobacco, Inc. (JP) 2007-11-14 EP disclosed
US-20060205731-A1 Novel aminopyridine compounds having Syk inhibitory activity JAPAN TOBACCO INC. (JP) 2006-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205731-A1 Novel aminopyridine compounds having Syk inhibitory activity SYK, BTK, ZAP70 KARS1 2175/4885SYK 1/4885JAK2 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.